Published in Thromb Haemost on December 08, 2016
The rise of fragment-based drug discovery. Nat Chem (2009) 2.46
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood (2010) 2.15
Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet (2002) 2.03
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. N Engl J Med (2015) 2.03
Fragment-based lead discovery: leads by design. Drug Discov Today (2005) 1.91
The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet (2013) 1.82
Effect of atorvastatin on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in healthy subjects. Pharmacotherapy (2008) 1.77
A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation. Am Heart J (2007) 1.73
Significant haemoglobinopathies: guidelines for screening and diagnosis. Br J Haematol (2010) 1.68
Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Pediatrics (2004) 1.60
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem (2002) 1.46
A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl (2002) 1.46
Long-term safety and efficacy of deferasirox (Exjade) for up to 5 years in transfusional iron-overloaded patients with sickle cell disease. Br J Haematol (2011) 1.45
Images in clinical medicine. Sister Mary Joseph's nodule. N Engl J Med (2005) 1.43
Experiences in fragment-based drug discovery. Trends Pharmacol Sci (2012) 1.41
Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. J Med Chem (2009) 1.39
Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure. Blood (2011) 1.37
Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood (2012) 1.28
Infection in sickle cell disease: a review. Int J Infect Dis (2009) 1.27
N-acetylcysteine and taurine prevent hyperglycemia-induced insulin resistance in vivo: possible role of oxidative stress. Am J Physiol Endocrinol Metab (2003) 1.25
Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure. Am J Physiol Endocrinol Metab (2006) 1.21
Prasugrel, a new thienopyridine antiplatelet drug, weakly inhibits cytochrome P450 2B6 in humans. J Clin Pharmacol (2008) 1.20
Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer (2012) 1.20
A simple, rapid, low-cost diagnostic test for sickle cell disease. Lab Chip (2013) 1.17
Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res (2004) 1.16
Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis. Clin Pharmacol Ther (2002) 1.14
The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration. Thromb Haemost (2008) 1.13
The 'rule of three' for fragment-based drug discovery: where are we now? Nat Rev Drug Discov (2013) 1.07
Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. Br J Haematol (2005) 1.05
Direct measure of insulin sensitivity with the hyperinsulinemic-euglycemic clamp and surrogate measures of insulin sensitivity with the oral glucose tolerance test: correlations with aberrant crypt foci promotion in rats. Cancer Epidemiol Biomarkers Prev (2003) 1.03
The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica (2011) 1.01
Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel. J Cardiovasc Pharmacol (2007) 0.97
Factors predicting future ACS episodes in children with sickle cell anemia. Am J Hematol (2014) 0.97
Lamin B-receptor mutations in Pelger-Huët anomaly. Br J Haematol (2003) 0.95
Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica (2010) 0.94
Simple paper-based test for measuring blood hemoglobin concentration in resource-limited settings. Clin Chem (2013) 0.94
Treatment with raloxifene for 2 years increases vertebral bone mineral density as measured by volumetric quantitative computed tomography. Bone (2004) 0.94
Management of sickle cell disease in the community. BMJ (2014) 0.93
A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol (2013) 0.93
Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial. Haematologica (2009) 0.93
Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol (2006) 0.93
Trials in sickle cell disease. Pediatr Neurol (2006) 0.92
Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. Br J Haematol (2007) 0.92
Deoxygenation-induced and Ca(2+) dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Cell Calcium (2011) 0.92
Group efficiency: a guideline for hits-to-leads chemistry. ChemMedChem (2008) 0.91
Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients. J Am Coll Cardiol (2013) 0.90
Reduction in platelet reactivity with prasugrel 5 mg in low-body-weight patients is noninferior to prasugrel 10 mg in higher-body-weight patients: results from the FEATHER trial. J Am Coll Cardiol (2012) 0.90
Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities? Prenat Diagn (2007) 0.89
Sickle Cell Disease. N Engl J Med (2017) 0.89
Switching directly to prasugrel from clopidogrel results in greater inhibition of platelet aggregation in aspirin-treated subjects. Platelets (2008) 0.88
Chronic transfusion practice for children with sickle cell anaemia and stroke. Br J Haematol (2008) 0.88
Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. Blood (2010) 0.87
Sickle Cell Disease. N Engl J Med (2017) 0.86
Transcranial Doppler scanning and the assessment of stroke risk in children with HbSC [corrected] disease. Arch Dis Child (2007) 0.86
Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects. Platelets (2009) 0.86
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease. J Pharmacokinet Pharmacodyn (2008) 0.85
Noninvasive transcutaneous Doppler ultrasound-derived hemodynamic reference ranges in Chinese adolescents. Pediatr Crit Care Med (2013) 0.85
Effects of portal free fatty acid elevation on insulin clearance and hepatic glucose flux. Am J Physiol Endocrinol Metab (2006) 0.85
Pial synangiosis in patients with moyamoya syndrome and sickle cell anemia: perioperative management and surgical outcome. Neurosurg Focus (2009) 0.85
Anionic cyclophanes as potential reversal agents of muscle relaxants by chemical chelation. Bioorg Med Chem Lett (2002) 0.85
The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia. Ann Hematol (2008) 0.85
Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants. Br J Clin Pharmacol (2012) 0.84
Hemoglobinopathies mimicking Hb S/beta-thalassemia: Hb S/S with alpha-thalassemia and Hb S/Volga. Am J Hematol (2006) 0.84
Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. Am J Hematol (2008) 0.84
Primary stroke prevention in Nigerian children with sickle cell disease (SPIN): challenges of conducting a feasibility trial. Pediatr Blood Cancer (2014) 0.83
Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin. Curr Med Res Opin (2012) 0.83
Rosai-Dorfman disease: a previously unreported association with sickle cell disease. BMC Clin Pathol (2007) 0.83
The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. Br J Haematol (2007) 0.83
Soluble CD163 levels in children with sickle cell disease. Br J Haematol (2011) 0.83
Measurement of systemic oxygen delivery and inotropy in healthy term neonates with the Ultrasonic Cardiac Output Monitor (USCOM). Early Hum Dev (2012) 0.83
A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost (2008) 0.82
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38. J Clin Pharmacol (2009) 0.81
Relationship between exposure to prasugrel active metabolite and clinical outcomes in the TRITON-TIMI 38 substudy. J Clin Pharmacol (2011) 0.81
Absence of "rebound" platelet hyperreactivity following cessation of prasugrel. Thromb Haemost (2011) 0.81
Outcome of adults with sickle cell disease admitted to critical care - experience of a single institution in the UK. Br J Haematol (2010) 0.81
Comparison of a new ELISA assay with the flow cytometric assay for platelet vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation in whole blood to assess P2Y(12) inhibition. Thromb Haemost (2011) 0.81
Accuracy of the ultrasonic cardiac output monitor in healthy term neonates during postnatal circulatory adaptation. Chin Med J (Engl) (2011) 0.81
Rickets and tracheobronchomalacia. BMJ Case Rep (2009) 0.80
Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol (2014) 0.80
Posterior fossa syndrome after surgical removal of a pineal gland tumor. Pediatr Neurol (2011) 0.79
A comparison of the VerifyNow P2Y12 point-of-care device and light transmission aggregometry to monitor platelet function with prasugrel and clopidogrel: an integrated analysis. J Cardiovasc Pharmacol (2010) 0.79
Health-related quality of life in children with sickle cell anemia: impact of blood transfusion therapy. Am J Hematol (2015) 0.79
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol (2013) 0.79
Urinary excretion of porphyrins, porphobilinogen and δ-aminolaevulinic acid following an attack of acute intermittent porphyria. J Clin Pathol (2013) 0.79